Stocks and Investing Stocks and Investing
Fri, September 6, 2024
Thu, September 5, 2024

Joon Lee Maintained (BMRN) at Strong Buy with Decreased Target to $118 on, Sep 5th, 2024


Published on 2024-10-28 14:06:46 - WOPRAI, Joon Lee
  Print publication without navigation


Joon Lee of Truist Securities, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $140 to $118 on, Sep 5th, 2024.

Joon has made no other calls on BMRN in the last 4 months.



There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 2 agree with Joon's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whitney Ijem of "Canaccord Genuity" Maintained at Hold and Held Target at $89 on, Thursday, July 25th, 2024
  • Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024


These are the ratings of the 7 analyists that currently disagree with Joon


  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $115 on, Wednesday, August 21st, 2024
  • William Pickering of "Bernstein" Upgraded from Hold to Buy and Increased Target to $110 on, Tuesday, August 20th, 2024
  • Phil Nadeau of "TD Cowen" Maintained at Strong Buy with Decreased Target to $120 on, Tuesday, August 6th, 2024
  • Cory Kasimov of "Evercore ISI Group" Maintained at Buy with Increased Target to $115 on, Tuesday, August 6th, 2024
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $110 on, Tuesday, August 6th, 2024
  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Monday, August 5th, 2024
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Thursday, June 27th, 2024
Contributing Sources